Organization
UCB Pharma, Morrisville, North Carolina, United States of America
2 abstracts
Abstract
BIMEKIZUMAB EFFICACY THROUGH 3 YEARS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: LONG-TERM POOLED ANALYSIS FROM BE BRIGHTOrg: UCB Pharma, Morrisville, North Carolina, United States of America, UCB Pharma, Monheim, Germany, UCB Pharma, Colombes, France,
Abstract
BIMEKIZUMAB IMPACT ON CARDIOVASCULAR INFLAMMATION MARKERS IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM PHASE 3 TRIALSOrg: Psoriasis Research and Treatment Center, Clinic of Dermatology, Venereology, and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Dalhousie University, Halifax, Nova Scotia, Canada, St Vincent’s University Hospital, Elm Park and the Charles Institute, University College Dublin, Dublin, Ireland,